Not specifiedRegulatory Approvalcompetitivemid-term

FDA Submission Update for ANDA215575 by QILU PHARM HAINAN

Importance6/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/4/2026, 12:34:14 AM

Assessment confidence: 59% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The submission of ANDA215575 by QILU PHARM HAINAN signals an increase in competition within the generic drug market. Portfolio teams must evaluate how this development may affect their market positioning and existing product lines. Regulatory context from FDA (FDA TA — ANDA215575) supports the near-term read. Assessment grounded in 21 ranked evidence items (6 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this submission on existing products and market positioning. The strongest clinical anchor is A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently (ClinicalTrials.gov), moderate corpus alignment. In Not specified, 7 regulatory and 4 competitive items passed relevance filtering for QILU PHARM HAINAN.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from FDA to Terminate Emergency Use Authorizations for COVID-19 Drugs. The submission indicates QILU PHARM HAINAN is advancing in the generic drug market, potentially increasing competition.

Regulatory Outlook

Regulatory risk is concentrated around FDA TA — ANDA215575 (FDA). Entity match (qilu pharm hainan); Regulatory pathway relevance (nda). The submission is under standard review, indicating no immediate regulatory concerns, but ongoing monitoring is necessary for approval updates.

Key Opportunities

The entry of a new generic product could impact market share and pricing strategies for existing products, potentially leading to revenue fluctuations.
Lead sponsor: Regeneron Pharmaceuticals. This study is researching a treatment combination with two experimental drugs called pozelimab and cemdisiran referred to as "study drugs". Researchers are looking for a better way to treat Paroxysmal Nocturnal Hemoglobinuria (PNH).
Lead sponsor: Sichuan Credit Pharmaceutical Co., Ltd.. An open-label, randomized, single dose study to assess dose proportionality and pharmacokinetic linearity in healthy participants under fasting condition.
Portfolio teams should assess the impact of this submission on existing products and market positioning.

What Would Change This Assessment

This becomes more urgent if Monitor the review progress and any subsequent approval announcements for ANDA215575.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA TA — ANDA215575
FDAhigh relevance
Entity match (qilu pharm hainan); Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — ANDA215575
FDAhigh relevance
Entity match (qilu pharm hainan); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ARGATROBAN IN 0.9% SODIUM CHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ROMVIMZA (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FLUOCINOLONE ACETONIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
Real-World Evidence Submissions to the Center for Drug Evaluation and Research
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Real-World Evidence Submissions to the Center for Biologics Evaluation and Research & the Center for Drug Evaluation and Research
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Methamphetamine Isomer Pharmacology in Humans
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
To Assess Dose Proportionality and Pharmacokinetic Linearity of Saninova Tablets in Healthy Participants Under Fasting Conditions
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA to Terminate Emergency Use Authorizations for COVID-19 Drugs
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves Allogeneic T Cell Immunotherapy for Hematologic Malignancies
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves TREGZI for Chronic GVHD in Blood Cancer Patients
Humanexa Signalsmedium relevance
Moderate corpus alignment

Immunotherapeutic landscape of amyotrophic lateral sclerosis: A bibliometric analysis of research trends, translational priorities, and collaboration networks (2006-2025).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Nanomedicine-based cancer immunotherapy: translational barriers, mechanistic strategies, and future perspectives.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Insect-based models in pharmaceutical ecotoxicology: a bibliometric and narrative review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Wedelactone-loaded exosomes for sepsis-induced liver injury: a novel therapeutic strategy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

QILU PHARM HAINAN

Commercial impact

medium

The entry of a new generic product could impact market share and pricing strategies for existing products, potentially leading to revenue fluctuations.

Regulatory impact

low

The submission is under standard review, indicating no immediate regulatory concerns, but ongoing monitoring is necessary for approval updates.

What to watch

Monitor the review progress and any subsequent approval announcements for ANDA215575.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.